What is Aravive?
Aravive, Inc. operates at the intersection of advanced molecular biology and clinical oncology. The company is primarily recognized for its development of AVB-500, an ultra-high affinity decoy protein engineered to inhibit the GAS6-AXL signaling pathway. By neutralizing this pathway, Aravive aims to impede tumor cell growth and metastasis, offering a transformative approach to cancer treatment. As a clinical-stage entity, the company maintains a rigorous focus on translational medicine, bridging the gap between laboratory discovery and patient-centric therapeutic solutions. Its market position is defined by its specialized intellectual property and its ability to attract institutional backing for high-stakes drug development.
How much funding has Aravive raised?
Aravive has raised a total of $136M across 2 funding rounds:
Stock Offering
$126M
Stock Offering
$10M
Stock Issuance/Offering (2014): $126M, investors not publicly disclosed
Stock Issuance/Offering (2022): $10M led by Eshelman Ventures
Key Investors in Aravive
Eshelman Ventures
A private investment entity with a strong focus on healthcare innovation and educational initiatives, often supporting transformative medical research.
Undisclosed Institutional Investor
An undisclosed institutional partner participating in the company's earlier financing rounds to support clinical development.
What's next for Aravive?
With the recent infusion of capital, Aravive is poised to transition into a more mature phase of clinical validation. The strategic roadmap likely involves expanding the scope of its clinical trials for AVB-500 and exploring potential combination therapies that leverage its unique decoy protein mechanism. As the company navigates the complexities of the oncology landscape, the focus will remain on achieving key regulatory milestones and demonstrating efficacy in patient populations. Investors and stakeholders are closely monitoring the firm's ability to translate its scientific platform into tangible clinical outcomes, which will be essential for long-term value creation and potential commercialization efforts in the competitive biotech sector.
See full Aravive company page
